CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...License Agreement • May 6th, 2020 • Forma Therapeutics Holdings, Inc., • Biological products, (no disgnostic substances) • New York
This [***] LICENSE AGREEMENT (this “Agreement”) is entered into and made effective as of December 28, 2018 (the “Effective Date”) by and among Forma Parent (solely for purposes of Articles 4, 5, 7 and 9) and Forma Inc. (as each such term is defined in Exhibit A), and Celgene Alpine Investment Company II, LLC, a Delaware limited liability company (“Celgene”). Forma Parent, Forma Inc. and Celgene are each referred to herein by name or as a “Party” or, collectively, as the “Parties.”
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...Collaboration and License Agreement • May 6th, 2020 • Forma Therapeutics Holdings, Inc., • Biological products, (no disgnostic substances) • New York
This COLLABORATION AND LICENSE AGREEMENT (the “Agreement”) is entered into and made effective as of the 21st day of December, 2011 (the “Effective Date”) by and between Forma Therapeutics, Inc., a Delaware corporation having its principal place of business at 500 Arsenal Street, Suite 100, Watertown, MA 02472, U.S. (“Forma”), and Boehringer Ingelheim International GmbH, a company existing under the laws of Germany, having its principal place of business at Binger Strasse 173, 55216 Ingelheim am Rhein, Germany (“BI”). Forma and BI are each referred to herein by name or as a “Party” or, collectively, as the “Parties”.
